SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is experiencing a massive, momentum-driven rally fueled by renewed market interest in clean energy infrastructure, specifically regarding the scaling of fuel cell technology for AI-driven data centers. While some community members celebrate the price appreciation, others are voicing skepticism based on the company's long-term history of dilution and previous reverse splits, creating a sharp divide between retail bulls expecting a breakout similar to industry peers and wary bears calling for a pullback.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is gaining momentum as investors eye potential M&A activity, with community discussion highlighting rumors of a buyout and the company's strategic pivot toward capital efficiency. The sentiment is fueled by heavy call option volume and signs of short covering, as the stock attempts to clear key resistance levels.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is facing significant volatility and market pressure due to a patent infringement lawsuit from Wolfspeed and broader sector rotation away from high-beta AI infrastructure plays. While community sentiment remains polarized, many investors are focused on the company's long-term potential in GaN and SiC power technology as they look for stabilization near key technical support levels.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending following a massive 20-year, $19 billion lease agreement with Anthropic for AI data center capacity, a catalyst that has sparked intense debate over the stock's valuation and the company's transformation into an AI infrastructure powerhouse. Community members are actively discussing whether the price action reflects legitimate market manipulation by short sellers or a typical 'sell the news' reaction, while others argue the deal validates the company's long-term potential as a critical player in the energy-intensive AI sector.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

IMMX is generating significant momentum as institutional accumulation continues ahead of anticipated BLA filings and upcoming clinical milestones. Investors are closely tracking its Breakthrough Therapy Designation for NXC-201 and potential M&A interest within the rare disease space, driving active discussions regarding the stock's valuation upside and institutional sentiment.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is experiencing intense volatility as investors weigh the impact of geopolitical tensions, shifting semiconductor demand, and the Federal Reserve's hawkish stance on interest rates. Community sentiment is deeply divided, with many traders focused on quick scalp opportunities and risk management as they debate whether the ongoing market fluctuations signal a healthy correction or a more significant bubble burst.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is gaining significant momentum as investors bet on the company's GLP-1 obesity pipeline, with community members actively discussing a potential breakout toward new highs. The stock is being closely monitored for a potential short squeeze as participants weigh the strength of its metabolic pipeline against the prospect of future M&A activity.

Penguin Solutions, Inc. engages in designing, building, and managing enterprise solutions. It operates through the following segments: Advanced Computing, Integrated Memory, and Optimized LED. The Advanced Computing segment offers platform solutions and services for artificial intelligence, high-performance computing, machine learning, advanced modeling, and the internet of things. The Integrated Memory refers to integrated memory solutions through the design and development. The Optimized LED segment comprises a broad portfolio of application-optimized LEDs. The company was founded in 1988 and is headquartered in Fremont, CA.

Penguin Solutions Inc.

Penguin Solutions is trending as investors react to a strong quarterly earnings report that highlighted record revenue growth driven by significant demand for AI infrastructure and integrated memory solutions. The community is actively debating the company's long-term sustainability due to its heavy reliance on AI spending, upcoming share dilution, and concerns about potential margin compression as memory market conditions evolve.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending as investors digest the commercial launch of NEREUS for motion sickness while speculating on a potential buyout, with many in the community debating the stock's low valuation and the firm's aggressive regulatory stance. Traders remain closely focused on the company's clinical pipeline, specifically the upcoming Phase 3 trial for GLP-1 related nausea, amidst active community discussions regarding persistent price volatility and institutional accumulation.

T1 Energy, Inc. engages in providing energy solutions focused on solar module and solar cell manufacturing. It focuses on building an integrated U.S. supply chain for solar and batteries. The company was founded by Tom Einar Jensen, Peter Matrai, and Tore Ivar Slettemoen on August 31, 2023 and is headquartered in Austin, TX.

T1 Energy Inc.

T1 Energy Inc. (TE) is currently experiencing high volatility driven by a mix of regulatory scrutiny regarding its supply chain and strong investor interest in its domestic solar manufacturing infrastructure, which is increasingly viewed as a key play for AI data center energy demand. Community sentiment remains sharply divided between investors betting on long-term growth and technical recoveryoften citing parallels to sector leaders like Bloom Energyand traders expressing frustration over rapid price swings and short-selling allegations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -4.12% and -19.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

New Treatment Modalities Are Reaching Cancers That Resisted Everything Else

New Treatment Modalities Are Reaching Cancers That Resisted Everything Else New Treatment Modalities Are Reaching Cancers That Resisted Everything Else PR Newswire VANCOUVER, BC, Feb. 17, 2026 Issued...

$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors

$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors $668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors PR Newswire VANCOUVER, BC, Jan. 30, 2026 Issued on behalf of...

Stevanato Group (STVN) Q3 Earnings and Revenues Surpass Estimates

Stevanato (STVN) delivered earnings and revenue surprises of +14.29% and +5.54%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Rigel Pharmaceuticals (RIGL) Tops Q3 Earnings and Revenue Estimates

Rigel (RIGL) delivered earnings and revenue surprises of +56.99% and +12.80%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Beats Revenue Estimates

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of +46.96% and +21.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Durect (DRRX) Reports Q2 Loss, Tops Revenue Estimates

Durect (DRRX) delivered earnings and revenue surprises of +46.15% and +39.69%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

electroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates

electroCore (ECOR) delivered earnings and revenue surprises of -9.38% and +0.83%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates

Amneal (AMRX) delivered earnings and revenue surprises of +38.89% and -0.15%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.

Perspective Therapeutics Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.25	--	--	N/A
Q1 '26	-$0.29	-$0.25	14.83%	BEAT
Q4 '25	-$0.35	-$0.51	-43.83%	MISSED
Q3 '25	-$0.32	-$0.35	-9.03%	MISSED
Q2 '25	-$0.29	-$0.30	-2.25%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

CATXPerspective Therapeutics Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest CATX News